Indivior Pharmaceuticals, Inc. Common Stock (INDV)

Price$37.62

Value ScoreD

Growth ScoreC

Momentum ScoreA

Favorite Metrics

Price vs S&P 500 (26W)4.02%

Price vs S&P 500 (4W)-4.76%

VGM Score56.71

Market Capitalization$4.59B

P/E Ratio (Annual)21.84x

All Metrics

P/CF (Annual)124.56x

Book Value / Share (Quarterly)$0.07

P/TBV (Annual)14.91x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)11.20%

Cash Flow / Share (Quarterly)$-0.75

Price vs S&P 500 (YTD)-3.32%

Gross Margin (TTM)80.16%

Net Profit Margin (TTM)16.94%

EPS (TTM)$1.63

10-Day Avg Trading Volume1.79M

EPS Excl Extra (TTM)$1.63

Revenue Growth (5Y)13.88%

EPS (Annual)$1.64

ROI (Annual)-13.72%

Gross Margin (Annual)84.10%

Net Profit Margin (5Y Avg)5.27%

Cash / Share (Quarterly)$1.56

P/E Basic Excl Extra (TTM)21.84x

Revenue Growth QoQ (YoY)20.13%

EPS Growth (5Y)-52.00%

P/E Normalized (Annual)21.84x

ROA (Last FY)17.49%

Revenue Growth TTM (YoY)4.38%

EBITD / Share (TTM)$2.13

ROE (5Y Avg)62.61%

Operating Margin (TTM)21.13%

Cash Flow / Share (Annual)$-0.75

P/B Ratio458.61x

P/B Ratio (Quarterly)230.24x

Net Income / Employee (Annual)$253,900

EV / Revenue (TTM)3.80x

Net Interest Coverage (TTM)11.39x

ROA (TTM)15.43%

EPS Growth QoQ (YoY)495.26%

EV / EBITDA (TTM)17.32x

EPS Incl Extra (Annual)$1.64

Current Ratio (Annual)0.71x

Quick Ratio (Quarterly)0.51x

3-Month Avg Trading Volume2.36M

52-Week Price Return176.78%

EV / Free Cash Flow (Annual)872.26x

P/E Incl Extra (TTM)21.84x

Revenue / Employee (TTM)$1,499,400

Tangible BV / Share (Quarterly)$1.16

P/S Ratio (Annual)3.70x

Asset Turnover (Annual)1.03x

52-Week High$41.00

Operating Margin (5Y Avg)5.27%

EPS Excl Extra (Annual)$1.64

CapEx CAGR (5Y)75.71%

26-Week Price Return11.95%

Quick Ratio (Annual)0.51x

13-Week Price Return17.36%

Total Debt / Equity (Annual)5.43x

Current Ratio (Quarterly)0.71x

Enterprise Value$4.71B

Revenue / Share Growth (5Y)17.00%

Asset Turnover (TTM)0.91x

Revenue / Employee (Annual)$1,498,200

Inventory Turnover (Annual)1.19x

Pretax Margin (Annual)19.29%

Cash / Share (Annual)$1.56

3-Month Return Std Dev43.48%

Gross Margin (5Y Avg)84.52%

Net Income / Employee (TTM)$253,900

EBITDA CAGR (5Y)-33.17%

EBITDA Interim CAGR (5Y)16.98%

ROE (Last FY)-88.24%

Net Interest Coverage (Annual)7.33x

EPS Basic Excl Extra (Annual)$1.64

P/FCF (TTM)21.94x

Receivables Turnover (TTM)4.89x

EV / Free Cash Flow (TTM)36.34x

Total Debt / Equity (Quarterly)27.90x

EPS Incl Extra (TTM)$1.63

Receivables Turnover (Annual)4.89x

ROI (TTM)29.40%

P/S Ratio (TTM)3.70x

Pretax Margin (5Y Avg)4.20%

Revenue / Share (Annual)$9.68

Tangible BV / Share (Annual)$0.86

Forward P/E12.20x

Free OCF CAGR (5Y)-48.94%

Price vs S&P 500 (52W)152.42%

P/E Ratio (TTM)21.84x

EPS Growth TTM (YoY)7022.71%

Year-to-Date Return4.84%

5-Day Price Return7.84%

EPS Normalized (Annual)$1.64

ROA (5Y Avg)3.81%

Net Profit Margin (Annual)16.95%

Month-to-Date Return4.43%

EBITD / Share (Annual)$2.05

EPS Growth (3Y)-74.29%

Operating Margin (Annual)21.15%

LT Debt / Equity (Annual)4.65x

P/CF (TTM)24.91x

ROI (5Y Avg)20.83%

P/E Excl Extra (TTM)21.84x

LT Debt / Equity (Quarterly)23.50x

EPS Basic Excl Extra (TTM)$1.63

P/TBV (Quarterly)12.23x

P/B Ratio (Annual)49.56x

Inventory Turnover (TTM)1.49x

Pretax Margin (TTM)19.27%

Book Value / Share (Annual)$0.37

Price vs S&P 500 (13W)9.11%

Net Margin Growth (5Y)-57.03%

Beta0.55x

P/FCF (Annual)917.22x

Revenue / Share (TTM)$9.47

ROE (TTM)159.06%

52-Week Low$13.42

vGradeD

gGradeC

mGradeA

vgmGradeC

Show chart for

Earnings Surprise History

Q1 260.96est. 0.67

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.23

4.25

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
INDVIndivior Pharmaceuticals, Inc. Common Stock	D	C	A	$37.62
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Indivior Pharmaceuticals specializes in treating opioid use disorder (OUD) through buprenorphine-based pharmaceutical products. Its primary revenue sources are Sublocade, an extended-release monthly injection, and Suboxone, a sublingual film combining buprenorphine and naloxone. The company addresses a significant therapeutic need in the management of opioid dependence as a chronic, treatable medical condition.